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Background: Ischemic preconditioning is a powerful mechanism of myocardial protection and in humans it can be
evaluated by sequential exercise tests. Coronary Artery Disease in the presence of diabetes mellitus may be
associated with worse outcomes. In addition, some studies have shown that diabetes interferes negatively with the
development of ischemic preconditioning. However, it is still unknown whether diabetes may influence the
expression of ischemic preconditioning in patients with stable multivessel coronary artery disease.
Methods/Design: This study will include 140 diabetic and non-diabetic patients with chronic, stable coronary artery
disease and preserved left ventricular systolic function. The patients will be submitted to two sequential exercise tests
with 30-minutes interval between them. Ischemic parameters will be compared between diabetic and non-diabetic
patients. Ischemic preconditioning will be considered present when time to 1.0 mm ST-segment deviation is greater in
the second of two sequential exercise tests. Exercise tests will be analyzed by two independent cardiologists.
Discussion: Ischemic preconditioning was first demonstrated by Murry et al. in dog’s hearts. Its work was reproduced by
other authors, clearly demonstrating that brief periods of myocardial ischemia followed by reperfusion triggers
cardioprotective mechanisms against subsequent and severe ischemia. On the other hand, the demonstration of
ischemic preconditioning in humans requires the presence of clinical symptoms or physiological changes difficult to be
measured. One methodology largely accepted are the sequential exercise tests, in which, the improvement in the time
to 1.0 mm ST depression in the second of two sequential tests is considered manifestation of ischemic preconditioning.
Diabetes is an important and independent determinant of clinical prognosis. It's a major risk factor for coronary artery
disease. Furthermore, the association of diabetes with stable coronary artery disease imposes worse prognosis,
irrespective of treatment strategy. It’s still not clearly known the mechanisms responsible by these worse outcomes.
Impairment in the mechanisms of ischemic preconditioning may be one major cause of this worse prognosis, but, in the
clinical setting, this is not known.
The present study aims to evaluate how diabetes mellitus interferes with ischemic preconditioning in patients with
stable, multivessel coronary artery disease and preserved systolic ventricular function.
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Ischemic preconditioning (IP) is a physiologic phenomenon
of tissue protection observed in many organs, including the
heart, in which brief periods of repetitive ischemia can pro-
tect cells from the corresponding area during a subsequent
ischemic insult. IP was first demonstrated by Murry et al.
in 1986 in canine hearts [1]. Through the interruption
in circumflex artery flow for 5 minutes, followed by
5 minutes of reperfusion, the authors promoted 4 cycles
of ischemia/reperfusion before a prolonged ischemic in-
sult of 40 minutes. When compared to the control
group, in which these brief ischemic stimuli were not
performed, the “preconditioned” group presented a 75%
reduction in the infarct area. This first work was then
reproduced by other authors, with similar results. This
phenomenon of myocardial protection is considered
the most powerful known mechanism of cardioprotec-
tion discovered so far.
The IP-related cardioprotection in the human myocar-
dium can be observed during percutaneous coronary
angioplasty after coronary occlusion with balloons [2],
during coronary artery bypass surgery with intermittent
clamping of the aorta [3] and in clinical studies [4,5].
Although ischemic preconditioning can be easily dem-
onstrated in experimental studies, in humans this is
more complex due to the fact that one needs to promote
myocardial ischemia in order to trigger the mechanisms
of cardioprotection. One methodology widely accepted
by literature is the sequential exercise tests (SET) [6-10].
During these tests, ischemic parameters like the time to
develop 1.0 mm ST depression in an electrocardiogram
print-out, the time to develop angina, the morphology of
ST depression, the total exercise time and the double-
product at the time of 1.0 mm ST-depression are regis-
tered in these two sequential tests and compared [9]. Pa-
tients are considered to present ischemic preconditioning
if they improve ischemic parameters in the second of two
tests [9,11]. The most widely accepted parameter to con-
sider the presence of IP is the improvement in the time to
1.0 mm ST depression [11,12].
In patients with chronic coronary artery disease
(CAD), diabetes is strongly associated with worse out-
comes [13]. And this is irrespective of the treatment ap-
plied [14]. Although these worse prognosis is not totally
understood, some studies infer that diabetes may nega-
tively interfere with the development of IP [15,16]. On
the other hand, experimental studies have demonstrated
equivocal results [17]. Thus, it`s still unknown whether
diabetes can influence the expression of IP in patients
with stable multivessel CAD.
Methods/Design
This study is an institutional project conducted at the
Heart Institute (InCor), Clinics Hospital, University ofSao Paulo, and is designed to prospectively investigate
the expression of ischemic preconditioning in 140 dia-
betic and non-diabetic patients with stable, multivessel
coronary artery disease, and preserved ventricular func-
tion. Of note, IP will be assessed by sequential exercise
tests and compared between diabetic and non-diabetic
patients.
This study is designed as a prospective cohort study, in
which patients with angiographically confirmed coronary
artery disease, preserved systolic ventricular function and
a recent ischemic treadmill exercise test will be included.
Before inclusion, all patients will undergo an outpatient
clinical evaluation. After inclusion, they will be submitted
to two sequential exercise tests, with a 30-minutes interval
between them. Ischemic parameters will be registered and
compared. IP will be assessed by an improvement is ische-
mic parameters in the second of two exercise tests, and its
manifestation and intensity will be compared between pa-
tients with diabetes and patients without diabetes mellitus
(Figure 1).
Patients
Consecutive patients followed in outpatient visits in our In-
stitution will be screened for inclusion and exclusion cri-
teria. Patients with angiographically confirmed multivessel
coronary artery disease (internal diameter reduction ≥70%
of at least two major coronary branches), stable symptoms
(Canadian class angina I-II), preserved left systolic ven-
tricular function confirmed by transthoracic echocardiog-
raphy (left ventricular ejection fraction ≥50%), and a recent
positive exercise stress test for myocardial ischemia (hori-
zontal or downsloping ST-segment depression ≥1.0 mm)
will be enrolled. Patients will not be included if they
present evidence of left ventricular hypertrophy, myo-
cardial infarction in the last 3 months, cardiomyopathy,
valvular disease, electrocardiogram changes, or conduction
defects that could unable the interpretation of ST-segment
ischemic changes, or renal or hepatic dysfunction.
After enrollment, patients will be discouraged from ac-
tivities likely to induce angina or that require the symp-
tomatic relief of short-acting nitrates. They will also be
advised to not use any anti-diabetic or cardiovascular
medications for 5 days before the exercise tests protocol.
Only nitrates will be permitted in order to control ische-
mic symptoms, but they will be withdrawn 12 h before
treadmill exercise tests. They will also be instructed not
to take caffeine for 24 h before their test. They will have
a 24-hour telephone number to contact study physicians
in case of worsening symptoms or any doubts on
medications.
Treadmill exercise tests
All patients will be submitted to computer-assisted tread-
mill exercise tests, symptom limited, using the Bruce
Figure 1 Flowchart of Study Design.
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interval between the consecutive tests will be 30 minutes.
A 12-lead electrocardiogram, heart rate and arterial blood
pressure will be obtained with the patient in standing pos-
ition at baseline. A 12-lead ECG will also be obtained at
each 1.0-min interval during exercise, at peak exercise,
each minute up to 5 min after the exercise phase, at the
onset of 1.0 mm ST-segment depression, at major ST-
segment deviation, at the onset of angina pectoris, and
when clinically relevant. The level of the ST-segment devi-
ation will be based on visual analyses of the 0.08 s after
the J point by two independent cardiologists in a blind
fashion. In case of disagreement, a third cardiologist will
be consulted and the matter will be resolved by consensus.
Only horizontal or downsloping ST-segment depressions
will be considered for the time to the onset of 1.0 mm ST-
segment depression evaluation (T-1.0 mm). Criteria for
interrupting the exercise test will be limiting chest pain,
physical exhaustion, ST-segment depression ≥3.0 mm,
ST-segment elevation ≥2.0 mm, maximum age-related
heart rate, severe arterial hypertension, severe arterial
hypotension, and complex or sustained arrhythmias.
The following parameters will be measured in all pa-
tients: resting heart rate and arterial blood pressure,
heart rate and arterial blood pressure at peak exercise,
T-1.0 mm in seconds, rate-pressure product (RPP) at
the onset of ST-segment depression and exercise dur-
ation in seconds.
IP analysis
The improvement in ischemic parameters in the second
test compared to the first one will indicate the presenceof IP. The parameters that will be used to evaluate IP
will be: T-1.0 mm and RPP. An improvement of at least
30 s in T-1.0 mm between the two sequential tests will
be used to consider IP present, as previously described
[11]. In the case of an improvement less than 30 s, an
improvement in RPP will also be used to indicate the
presence of IP.
Statistical analysis
All data will be expressed as means ± standard deviation
or median ± interquartile range, as appropriate. For cat-
egorical variables, the Fisher`s exact test will be used.
Continuous variables not distributed normally, as evalu-
ated by the Kolmogorov-Smirnov test, will be compared
by the Mann–Whitney test. Continuous variables with a
normal distribution will be compared by the Student’s t
test. All tests will be 2-tailed, and statistical significance
will be assumed when P < 0.05. Statistical analyses will
be performed using the software SPSS, version 17.0.
Sample size
The aim of the present study will be to detect differences
in the occurrence and magnitude of IP assessed by se-
quential treadmill exercise tests, using T-1.0 mm in dia-
betic and non-diabetic patients as the main parameter
evaluated. Therefore, the sample size calculation is based
on previous studies’ differences in IP between groups of
diabetic and non-diabetic patients. Based on these stud-
ies, the observed improvement in time to 1.0 mm ST-
deviation in diabetic patients was 87 s ± 44 s [18] and
the improvement in non-diabetic patients was 123 ± 65 s
[19]. Thus, accounting for a loss of 30% of patients who
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search group), 70 patients with diabetes and 70 patients
without diabetes need to be studied to be able to test the
null hypothesis that the population means are equal
(power = 0.9 and alpha = 0.05).
Discussion
There is no study in humans so far which have assessed
the differences in IP between patients with and without
diabetes and chronic coronary artery disease.
Diabetes is a known clinical condition associated with
the development of ischemic heart disease [20], and in pa-
tients with established cardiovascular diseases, diabetes
confers a worse prognosis [13,14]. Besides the fact that
diabetes interferes in many stages in the development and
progression of coronary artery disease, it`s postulated that
diabetic patients seem to be more susceptible to ischemic
injury [21,22]. Although some studies with humans during
percutaneous coronary intervention [15] or during the
clinical context of an acute myocardial infarction [16]
show that diabetes interferes negatively with IP, experi-
mental studies have demonstrated conflicting results [17].
However, the comparison of these results is controversial
by many reasons, and mostly by the duration, severity and
the type of diabetes and by different study protocols. Be-
sides, end points also differ between studies, as well as the
protocol of ischemia, the intensity of ischemia (zero flow
versus low-flow ischemia) and the presence of the reperfu-
sion phase. Furthermore, differences between species in
relation to coronary collaterals and in myocardial perfu-
sion may contribute to the variability of the results.
Moreover, these differences between clinical and experi-
mental studies may be due to the contribution of other
diseases in diabetic patients, such as hypertension, dislypi-
demia, microvascular dysfunction, neuropathy, nephropa-
thy, as well as the use of antidiabetic drugs which may
block IP by preventing the opening of K(ATP) channels in
the myocardium [23,24]. The interaction among all these
conditions may determine the overall response of the myo-
cardium to ischemia in patients with diabetes mellitus.
The complex physiopathology of diabetes associated
with interactions with its associated comorbidities,
among them the aterosclerotic macrovascular disease,
make this syndrome one of the greatest challenges of
this century. The interaction of diabetes with cardiopro-
tective mechanisms is of particular interest in clinical
practice. Thus, the aim of the present study will be to
analyze ischemic preconditioning in diabetic and non-
diabetic patients with chronic, stable coronary artery dis-
ease by sequential treadmill exercise tests.
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